Clinical trial
Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of…
NCT00129974 · Tufts Medical Center, Other · Terminated
Key facts
| NCT number | NCT00129974 |
|---|---|
| Title | Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer |
| Official title | A Phase II Trial of Pemetrexed in Combination With Gemcitabine as First Line Treatment in Extensive-Stage Small Cell Lung Carcinoma |
| Lead sponsor | Tufts Medical Center, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Small Cell |
| Intervention type | Drug |
| Interventions | pemetrexed and gemcitabine |
| Enrollment | 1 |
| Start date | Aug 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Aug 12, 2005 |
| Last update posted | Jun 16, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: